Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 13 , ISSUE 3 ( July-September, 2024 ) > List of Articles

Original Article

Effectiveness, Utility, and Economic Analysis of Three-drug Treatment vs Two-drug Treatment in Chronic Obstructive Pulmonary Disease Patients

Aamir A Syed, Subhranshu Panda, Aleemuddin NM

Keywords : Chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease assessment test, Health-related quality of life, Incremental Cost-effectiveness ratio, St George respiratory questionnaire, Triple therapy

Citation Information : Syed AA, Panda S, NM A. Effectiveness, Utility, and Economic Analysis of Three-drug Treatment vs Two-drug Treatment in Chronic Obstructive Pulmonary Disease Patients. Indian J Respir Care 2024; 13 (3):146-151.

DOI: 10.5005/jp-journals-11010-1126

License: CC BY-NC 4.0

Published Online: 30-09-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim and background: Inhaled corticosteroids (ICS) and bronchodilators remain the mainstay of therapeutic modalities available for the management of chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the effectiveness, utility, and economic analysis of a three-drug treatment vs a two-drug treatment in COPD patients. Materials and methods: An observation was conducted at a superspecialty hospital in Hyderabad. Out of the 115 patients recruited from the inpatient and outpatient wards of the Pulmonology Department, 55 patients received triple therapy containing ICS, long-acting β-agonists (LABA), and long-acting muscarinic antagonists (LAMA), whereas 60 patients were treated with dual therapy comprising ICS/LABA. Cost-effectiveness was assessed based on forced expiratory volume in 1 second (FEV1) (FEV1% predicted), St George's respiratory questionnaire (SGRQ) scores, SGRQ responder ratio, COPD assessment test (CAT) scores, and incremental cost-effectiveness ratio (ICER). Results: Results signified the enhanced potency of three-drug treatment vs two-drug treatment as proven by the improvement in average difference from initial values in (1) FEV1% predicted value of 4.36 [95% confidence interval (CI) (2.9–5.82)], (2) SGRQ scores of −6.76 [95% CI (−2.14 to −11.38)], SGRQ responder ratio of 13.25 (3.72–47.24), CAT scores of −5.15 [95% CI (−9.87 to −0.43)] and ICER of 3522 [95% CI (14682 to −7638)]. Conclusion: Triple therapy comprising LABA, LAMA, and ICS can optimize lung function and improve clinical outcomes, leading to overall enhancement of well-being compared to LABA/ICS dual therapy in moderate to severe COPD patients. Clinical significance: Three-drug treatment comprising ICS/LABA/LAMA is an effective and cost-effective therapeutic approach for managing moderate and severe COPD compared to ICS/LABA dual therapy. This is evidenced by improvements in spirometry values (FEV1% predicted) and health-related quality of life (HRQoL).


PDF Share
  1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990 2020: global burden of disease study. Lancet 1997;349(9064):1498–1504. DOI: 10.1016/S0140-6736(96)07492-2
  2. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138(1):16–27. DOI: 10.1016/j.jaci.2016.05.011
  3. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death [last accessed 24th February 2024]
  4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2024. Available at https://goldcopd.org/2024-gold-report/ [Last accessed 24th February 2024].
  5. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378(18):1671–1680. DOI: 10.1056/NEJMoa1713901
  6. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196(4):438–446. DOI: 10.1164/rccm.201703-0449OC
  7. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6(10):747–758. DOI: 10.1016/S2213-2600(18)30327-8
  8. Palermo TM, Long AC, Lewandowski AS, et al. Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. J Pediatr Psychol 2008;33(9):983–996. DOI: 10.1093/jpepsy/jsn038
  9. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016;21(1):14–23. DOI: 10.1111/resp.12660
  10. Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, et al. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2016;20(1):11–23. DOI: 10.5588/ijtld.15.0472
  11. Hounton S, Newlands D. Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage. Cost Eff Resour Alloc 2012;10(1):8. DOI: 10.1186/1478-7547-10-8
  12. Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis 2019;14:2681–2695. DOI: 10.2147/COPD.S216072
  13. Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis 2020;15:1621–1632. DOI: 10.2147/COPD.S240556
  14. Schroeder M, Shah D, Risebrough N, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a UK perspective. Respir Med 2019;1:100008. DOI: 10.1016/j.yrmex.2019.100008
  15. Driessen M, Shah D, Risebrough N, et al. Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: a UK perspective. Respir Med 2018;145:130–137. DOI: 10.1016/j.rmed.2018.10.024
  16. Jones PW, Quirk FH, Baveystock CM. The St. George's respiratory questionnaire. Resp Med 1991;85(Suppl B):25–31. DOI: 10.1016/s0954-6111(06)80166-6
  17. Barr JT, Schumacher GE, Freeman S, et al. American translation, modification, and validation of the St. George's respiratory questionnaire. Clin Ther 2000;22(9):1121–1145. DOI: 10.1016/S0149-2918(00)80089-2
  18. Jo YS, Yoon HI, Kim DK, et al. Comparison of COPD assessment test and clinical COPD questionnaire to predict the risk of exacerbation. Int J Chron Obstruct Pulmon Dis 2017;13:101–107. DOI: 10.2147/COPD.S149805
  19. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J 2009;34(3):648–654. DOI: 10.1183/09031936.00102509
  20. Starkie HJ, Briggs AH, Chambers MG, et al. Predicting EQ-5D values using the SGRQ. Value Health 2011;14(2):354–360. DOI: 10.1016/j.jval.2010.09.011
  21. Sharma GN, Ali SA, Shrivastav B, et al. Three-drug therapy versus two-drug therapy for management of patient-reported manifestations and quality of life in chronic obstructive pulmonary disease patients: a meta-analysis. J Appl Pharm Sci 2020;10(10):036–049. DOI: 10.7324/JAPS.2020.10104
  22. Syed AA, Sharma GN, Shrivastav B, et al. Metaanalysis of cost-effectiveness of three-drug therapy versus two-drug therapy in chronic obstructive pulmonary disease patients. J Appl Pharm Sci 2021;11(9):129–138. DOI: 10.7324/JAPS.2021.110916
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.